Comparative two-dimensional NKG2A/CD94 cell membrane chromatography for targeted screening immune checkpoint inhibitors
Journal of Pharmaceutical Analysis · 2026-02 · 16 (2) · 101259
DOI: 10.1016/j.jpha.2025.101259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-02. Verfasst von Yanting Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
The natural killer (NK) group 2 member A/C-type lectin domain family 4 member A (NKG2A/CD94) heterodimeric receptor is commonly recognized as a crucial immune checkpoint in NK cells. Currently, there is a notable lack of small-molecule inhibitors specifically targeting NKG2A that have progressed to clinical trials, and established screening methodologies for identifying such inhibitors remain limited. Cell membrane chromatography (CMC) is a biochromatographic technique that leverages the specific interactions between membrane receptors and their ligands. In this study, a comprehensive two-dimensional (2D) NKG2A/CD94 and HEK293 CMC comparative analysis system was developed to screen for selective NKG2A/CD94 ligands derived from Echinacea purpurea (L.) Moench (EP) and Alpinia katsumadai Hayata (AKH). The comprehensive 2D CMC comparative analysis system demonstrated superior selection performance, resulting in the successful screening and identification of five compounds. Of these compounds, chicoric acid and alpinetin exhibited greater binding affinity for the NKG2A/CD94 CMC column compared to the HEK293 CMC column, leading to their selection for further efficacy verification. Surface plasmon resonance (SPR) analysis revealed that chicoric acid and alpinetin exhibit binding affinities of 12.9 and 9.49 μM, to NKG2A/CD94. Molecular docking analyses and pharmacological investigations further demonstrated that both compounds could influence NK cell activation by interacting with the NKG2A/CD94. These findings suggest their potential as novel NKG2A/CD94 immune checkpoint inhibitors (ICIs). Additionally, the comprehensive 2D CMC system serves as a robust and practical platform for drug discovery, and could be applied to other immune checkpoint receptor models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China.
- School of Pharmacy, Naval Medical University (Second Military Medical University), Shanghai, 200433, China.
- Department of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201999, China.
- Beijing University of Chinese Medicine, Beijing, 102488, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Li, Y., Gu, Y., Zhang, W., Li, T., Chen, C., Wang, C., Chai, Y., Ma, X., & Chen, X. (2026). Comparative two-dimensional NKG2A/CD94 cell membrane chromatography for targeted screening immune checkpoint inhibitors. Journal of Pharmaceutical Analysis, 16(2), 101259. https://doi.org/10.1016/j.jpha.2025.101259
Vancouver
Li Y, Gu Y, Zhang W, Li T, Chen C, Wang C, et al. Comparative two-dimensional NKG2A/CD94 cell membrane chromatography for targeted screening immune checkpoint inhibitors. Journal of Pharmaceutical Analysis. 2026;16(2):101259. doi:10.1016/j.jpha.2025.101259
BibTeX
@article{Li2026,
author = {Li, Yanting and Gu, Yanqiu and Zhang, Weiyue and Li, Tianhua and Chen, Chun and Wang, Chengliang and Chai, Yifeng and Ma, Xueqin and Chen, Xiaofei},
title = {Comparative two-dimensional NKG2A/CD94 cell membrane chromatography for targeted screening immune checkpoint inhibitors},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
volume = {16},
number = {2},
pages = {101259},
doi = {10.1016/j.jpha.2025.101259}
}
EUVIMED